Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
Edesa Biotech, Inc. - Common Shares (EDSA)
Company Research
Source: GlobeNewswire
Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisional patent applications for sepsis, acute kidney injury and pneumoniaStrategic collaborations to support late-stage development and commercialization being evaluatedStudy results selected for oral presentation at ATS 2026 conference TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today positive additional data from a Phase 3 study of paridiprubart. The results represent a broader, 278-patient population, which includes both previously reported 104 patients requiring invasive mechanical ventilation (IMV) as well as 174 non-IMV patients. Across this full population, the company’s first-in-class anti-TLR4 antibody demonstrated
Show less
Read more
Impact Snapshot
Event Time:
EDSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDSA alerts
High impacting Edesa Biotech, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
EDSA
News
- Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Edesa Biotech (EDSA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EDSA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "MarketBeat
- Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit [Yahoo! Finance]Yahoo! Finance
- Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit [TheStreet.com]TheStreet.com
- Edesa Biotech Invited for Oral Showcase at Respiratory Innovation SummitGlobeNewswire
EDSA
Sec Filings
- 4/10/26 - Form 4
- 4/3/26 - Form ARS
- 4/3/26 - Form DEFA14A
- EDSA's page on the SEC website